Bristol Myers Squibb acquires global rights to BioArctic’s Alzheimer’s antibody candidates BAN1503 and BAN2803 for up to $1.3 ...

Seoul Asan Medical Center said it started prescribing the early Alzheimer's disease drug "Leqembi" (generic name lecanemab) ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Lecanemab (Leqembi) and donanemab (Kisunla) have both received FDA approval as amyloid-beta targeting therapies.⁷⁻⁸ Several ...

Alzheimer’s disease treatment has undergone a significant transformation in recent years, experts say. A shift from symptom ...

Currently, the only two Alzheimer’s medications approved for market by the U.S. Food and Drug Administration (FDA) are ...

The WVU Rockefeller Neuroscience Institute (RNI) is providing patients greater statewide and regional access to a ...

Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.

The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live ...